13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Anti‐programmed cell death‐1 (PD‐1) antibodies are regarded as a risk factor for insulin‐dependent diabetes mellitus as a side‐effect. While a small number of cases have been reported, evidence remains limited. This is the first report of an Asian patient developing insulin‐dependent diabetes during anti‐PD‐1 therapy. A 55‐year‐old euglycemic woman receiving nivolumab for malignant melanoma showed abrupt onset of ketonuria, and elevated levels of plasma glucose (580 mg/dL) and hemoglobin A1c (7.0%). Over the next 2 weeks, serum C‐peptide levels fell below the limit of detection. Islet autoantibodies were negative, and the patient showed a human leukocyte antigen haplotype associated with type 1 diabetes. Anti‐PD‐1 therapy can cause rapid onset of insulin‐dependent diabetes, possibly because of inappropriate activation of T cells. Human leukocyte antigen haplotypes might be related to the onset of this disease. Physicians should be aware of this serious adverse event and carry out routine blood glucose testing during anti‐PD‐1 therapy.

          Related collections

          Author and article information

          Contributors
          hiro-405@cb3.so-net.ne.jp
          Journal
          J Diabetes Investig
          J Diabetes Investig
          10.1111/(ISSN)2040-1124
          JDI
          Journal of Diabetes Investigation
          John Wiley and Sons Inc. (Hoboken )
          2040-1116
          2040-1124
          31 May 2016
          November 2016
          : 7
          : 6 ( doiID: 10.1111/jdi.2016.7.issue-6 )
          : 915-918
          Affiliations
          [ 1 ] Department of Endocrinology, Metabolism, Rheumatology and Nephrology Faculty of MedicineOita University OitaJapan
          Author notes
          [*] [* ] Correspondence

          Hirotaka Shibata

          Tel.: +81‐97‐586‐5793

          Fax: +81‐97‐549‐4480

          E‐mail address: hiro-405@ 123456cb3.so-net.ne.jp

          Article
          JDI12531
          10.1111/jdi.12531
          5089956
          27181090
          31d837a1-01ce-4a58-85f5-4661ef1df87c
          © 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd

          This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

          History
          : 16 December 2015
          : 14 March 2016
          : 11 April 2016
          Page count
          Figures: 0, Tables: 2, Pages: 4, Words: 2282
          Categories
          Case Report
          Articles
          Clinical Science and Care
          Custom metadata
          2.0
          jdi12531
          November 2016
          Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.6 mode:remove_FC converted:01.11.2016

          anti‐programmed cell death‐1 antibodies,fulminant type 1 diabetes,nivolumab

          Comments

          Comment on this article